Lifesaver to litigant: how a Covid-19 drug drove a wedge between Max Healthcare and Novacare


Ronapreve came as a boon at the peak of the Delta wave in 2021. But as the injection turned ineffective against the Omicron variants, stocks piled up. While Novacare, the distributor, says Max defaulted on dues, the hospital group alleges misrepresentation in the matter. However, the dispute highlights larger issues regarding risks related to innovative drugs and pharma cold chains.

The pandemic may have receded, but its aftermath continues to roll. Besides the shadow it cast on the lives of millions across the world, the toll it has taken on various other spheres of life and business is still unfolding. Take the case of Novacare Health Solutions, a large distributor of medicines, which has filed a petition in the National Company Law Tribunal in Mumbai against Max Healthcare, one of India’s leading hospital chains,

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *